Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

  • End date
    Jan 31, 2023
  • participants needed
  • sponsor
    Johns Hopkins University
Updated on 16 April 2021
David J Sullivan, MD
Primary Contact
MedStar Washington Hospital Center (1.7 mi away) Contact
+30 other location
coronavirus infection


To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.


The purpose of this randomized, double-blind, controlled, phase 2 trial is to evaluate the efficacy of treatment with HCIP in reducing hospitalization and death prior to hospitalization among outpatient adults who have RNA detection test-confirmed COVID-19 AND have developed any symptoms of COVID-19 including but not limited to fever, cough, or other COVID associated symptoms like anosmia. Ambulatory/outpatient adults subjects 18 years of age or older, regardless of risk factors for severe illness may participate. A total of approximately 1344 eligible subjects stratified 50:50 in the <65 vs 65 age range will be randomized in a 1:1 ratio to receive either HCIP or control plasma.

Condition SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, SARS-CoV 2, Sars Cov 2
Treatment SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
Clinical Study IdentifierNCT04373460
SponsorJohns Hopkins University
Last Modified on16 April 2021


Yes No Not Sure

Inclusion Criteria

years of age
Competent and capable to provide informed consent
Positive RNA test for presence of SARS-CoV-2 in fluid collected by oropharyngeal or nasopharyngeal swab
Experiencing any symptoms of COVID-19 including but not limited to fever(T> 100.5 F), cough, or other COVID associated symptoms like anosmia
days since the first symptoms of COVID-19
days since first positive SARS-CoV-2 RNA test
Able and willing to comply with protocol requirements listed in the informed consent

Exclusion Criteria

Hospitalized or expected to be hospitalized within 24 hours of enrollment
Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance
History of prior reactions to transfusion blood products
Inability to complete therapy with the study product within 24 hours after enrollment
Receiving any treatment drug for COVID-19 within 14 days prior to screening evaluation (off label like hydroxychloroquine, compassionate use or study trial related)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note